Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)

D. Jackson Coleman; Winston Lee; Suzanne Daly; Mark P. Breazzano; Janet Sparrow; Stephen H. Tsang

American Journal of Ophthalmology Case Reports (Mar 2021)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)

D. Jackson Coleman,
Winston Lee,
Suzanne Daly,
Mark P. Breazzano,
Janet Sparrow,
Stephen H. Tsang

Affiliations

D. Jackson Coleman: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA; Corresponding author. Edward S. Harkness Eye Institute, Columbia University Medical Center, 635 West 165th Street New York, NY, 10032, USA.
Winston Lee: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA
Suzanne Daly: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA
Mark P. Breazzano: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA
Janet Sparrow: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA
Stephen H. Tsang: Edward S. Harkness Eye Institute, Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA; Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative, Departments of Ophthalmology, Pathology & Cell Biology, Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA

Journal volume & issue: Vol. 21
p. 100998

Abstract

Read online

Purpose: Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). Observations: In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy. Conclusions: AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.

Published in American Journal of Ophthalmology Case Reports

ISSN: 2451-9936 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Ophthalmology
Website: http://www.journals.elsevier.com/american-journal-of-ophthalmology-case-reports/

About the journal

Abstract

Keywords